Digital & Innovation
Novartis buys Amblyotech to develop novel digital therapy for ‘lazy eye’
Digital & Innovations: Novartis completed the acquisition of Amblyotech, a software startup, and will pursue the development of the acquired digital technology for the treatment of amblyopia (lazy eye).
The condition can lead to poor vision and other quality of life issues if left untreated. The condition can impact children and adults beyond their vision, making it difficult to drive and maintain a sense of autonomy. Current treatment options, including patching and/or atropine, are associated with low compliance and low success rates. Approved therapies for adults are limited.
Designed to enhance compliance, Amblyotech utilises active gaming and passive video technology with 3-D glasses, training the eyes to work together to view an image in full. Its software employs a unique visual presentation, called dichoptic display, where each eye is presented with different images using a proprietary algorithm. In early clinical studies, Amblyotech’s software demonstrated improvements in vision in both children and adults with faster onset compared to standard of care treatments.
HCP engagement during COVID-19. Fill the gap of reduced field force activities. Health Industry Hub combines expertise in delivering digital health content with high engagement and 20+ years industry experience. By industry for industry. Contact us.
“By offering a non-invasive solution that has the potential to be significantly faster than current standards of care such as patching for children and adults impacted by lazy eye, Amblyotech’s software is a great example of how we can reimagine medicine using digital technology,” said Nikos Tripodis, Global Business Franchise Head, Ophthalmology.
With the transaction closing, Novartis plans to work in partnership with video game developer, Ubisoft, to develop the Amblyotech software as a medical device (SaMD), create a series of engaging games for the device, and conduct a proof of concept study (PoC), planned for later in 2020.
Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
News & Trends - Biotechnology
AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm
Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]
MoreNews & Trends - MedTech & Diagnostics
Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis
MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]
MoreNews & Trends - MedTech & Diagnostics
Cardiac device benefits face more cuts, while technical services remain secure in the short term
MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]
MoreNews & Trends - Biotechnology
CSL’s world-first gene therapy heads for MSAC evaluation
Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]
More